Legend Biotech (LEGN) reshapes board as GenScript chair joins, two directors exit

Rhea-AI Filing Summary

Legend Biotech Corporation reported several board changes effective January 20, 2026. The company appointed Robin Meng, chairman and executive director of GenScript, as a Class III director with a term running until the 2026 annual general meeting of shareholders. GenScript is Legend Biotech’s largest shareholder and the companies are party to related-party agreements previously described in Legend Biotech’s Form 20-F for the year ended December 31, 2024.

Two directors, Dr. Li Zhu and Yau Wai Man Philip, resigned from the Board, and each resignation was stated not to result from any dispute or disagreement over Legend Biotech’s operations, policies, or practices. In recognition of Mr. Yau’s service, the Compensation Committee approved accelerated vesting of his unvested restricted share units and a one-time cash payment of $56,250, equal to his remaining 2026 board compensation. Following his resignation, Tomas Heyman was appointed chair of the Audit Committee.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

Date of Report: January 23, 2026

Commission File Number: 001-39307

Legend Biotech Corporation

(Exact Name of Registrant as Specified in its Charter)

2101 Cottontail Lane

Somerset, New Jersey 08873

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  ☒            Form 40-F  ☐

Legend Biotech Appoints Robin Meng to its Board of Directors

Legend Biotech Corporation (“Legend Biotech”) announced, effective January 20, 2026 (the “Effective Date”), its Board of Directors (the “Board”) appointed Robin Meng to the Board as a Class III director, with an initial term until Legend Biotech’s 2026 annual general meeting of shareholders. Mr. Meng was appointed to replace Dr. Li Zhu who resigned from the Board on the Effective Date (as described above).

Mr. Meng has significant experience in senior leadership, finance, and corporate governance in the life sciences and biotechnology sector. He is the chairman and an executive Director of GenScript, and has been employed at GenScript in various roles since 2010. Prior to joining GenScript, Mr. Meng served in finance roles at Quay Magnesium, Saint Gobain Grains, and Schering-Plough China. He holds a Bachelor of Engineering from Changsha University of Science and Technology and a Master of Finance from Queen’s University in, Canada.

There are no arrangements or understandings between Mr. Meng and any other persons pursuant to which Mr. Meng was appointed as a director. As disclosed above, Mr. Meng is the chairman and an executive Director of GenScript, Legend Biotech’s largest shareholder. Legend Biotech is party to a number of agreements with GenScript that are related-party transactions and described in Legend Biotech’s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission on March 11, 2025. Other than Legend Biotech’s agreements with GenScript, there are no related-party transactions in which Mr. Meng has an interest requiring disclosure.

Resignation of Directors

On January 20, 2026, Dr. Li Zhu and Yau Wai Man Philip resigned from the Board, effective as of the Effective Date. Each resignation was not the result of any dispute or disagreement with Legend Biotech on any matter relating to its operations, policies (including accounting or financial policies) or practices.

In recognition of Mr. Yau’s substantial contributions to Legend Biotech as a member of the Board and the Audit Committee of the Board, the Compensation Committee of the Board also approved the accelerated vesting of unvested shares underlying Mr. Yau’s outstanding restricted share units, effective as of the Effective Date, as well as a one-time payment to Mr. Yau equal to his remaining annual cash compensation for service as a member of the Board for the remainder of 2026 (equal to $56,250).

Following Mr. Yau’s resignation, Tomas Heyman was appointed as the chair of Audit Committee of the Board, effective as of the Effective Date.

This report on Form 6-K shall be deemed to be incorporated by reference in the registration statements of Legend Biotech on Form F-3 (Nos. 333-278050, 333-257625, and 333-272222) and Form S-8 (No. 333-239478 and 333-283217), to the extent not superseded by documents or reports subsequently filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		LEGEND BIOTECH CORPORATION
Date: January 23, 2026		By:	/s/ Ying Huang
		Name:	Ying Huang, Ph.D.
		Title:	Chief Executive Officer

FAQ

What board changes did Legend Biotech (LEGN) announce in this Form 6-K?

Legend Biotech announced that Robin Meng was appointed to its Board as a Class III director, while Dr. Li Zhu and Yau Wai Man Philip resigned from the Board, all effective January 20, 2026.

Who is Robin Meng and what is his relationship to Legend Biotech (LEGN)?

Robin Meng has senior leadership and finance experience in life sciences and biotechnology. He is the chairman and an executive Director of GenScript, which is Legend Biotech’s largest shareholder and a counterparty in several related-party agreements described in Legend Biotech’s Form 20-F for the year ended December 31, 2024.

Did the resignations from Legend Biotech’s (LEGN) Board involve any disputes?

The company stated that the resignations of Dr. Li Zhu and Yau Wai Man Philip were not the result of any dispute or disagreement with Legend Biotech regarding its operations, policies (including accounting or financial policies), or practices.

What compensation did Legend Biotech (LEGN) approve for outgoing director Yau Wai Man Philip?

The Compensation Committee approved accelerated vesting of Mr. Yau’s unvested restricted share units and a one-time cash payment of $56,250, equal to his remaining annual cash compensation for serving on the Board for the remainder of 2026.

Who became chair of Legend Biotech’s (LEGN) Audit Committee after the board changes?

Following the resignation of Yau Wai Man Philip, Tomas Heyman was appointed as the chair of the Audit Committee of the Board, effective January 20, 2026.

How is this Legend Biotech (LEGN) Form 6-K used with existing registration statements?

This Form 6-K is deemed incorporated by reference into Legend Biotech’s registration statements on Form F-3 (Nos. 333-278050, 333-257625, 333-272222) and Form S-8 (Nos. 333-239478, 333-283217), except to the extent later filings supersede it.